recombinant hepatitis B vaccine (Southeast University)

The engineered HB vaccine (Southeast University) is a recombinant protein subunit vaccine containing the Hepatitis B surface antigen (HBsAg). It is produced using recombinant DNA technology, typically expressed in yeast or mammalian cell lines. The vaccine is designed to provide active immunity against the Hepatitis B virus (HBV) by stimulating the host's immune system to produce neutralizing antibodies (anti-HBs). In the clinical context associated with Southeast University, this vaccine is administered in a 20 µg dose to newborns of HBsAg-positive mothers as part of an immunoprophylaxis regimen (often in combination with Hepatitis B Immune Globulin) to prevent the vertical or perinatal transmission of HBV. This intervention is critical for reducing the risk of chronic Hepatitis B infection in children born to highly viremic mothers.

Other names

genetically engineered HB vaccineHBsAg vaccinerecombinant Hepatitis B surface antigen vaccine